Metabolome analysis: An introduction Silas G. Villas-Bôas Ute Roessner Michael A. E. Hansen Jørn Smedsgaard Jens Nielsen wiley-interscience series in mass spectrometry series editors Dominic M. Desiderio and Nico M.M. Nibbering

2007 ◽  
Vol 18 (8) ◽  
pp. R1-R2
Author(s):  
Lloyd W. Sumner
Keyword(s):  
Mass Spectrometry ◽  
Metabolome Analysis

scholarly journals Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells ◽  
2018 ◽  
Vol 8 (1) ◽  
pp. 14 ◽  
Author(s):  
Shin-Ichi Ueno ◽  
Shinji Saiki ◽  
Motoki Fujimaki ◽  
Haruka Takeshige-Amano ◽  
Taku Hatano ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Severity ◽  
Rating Scale ◽  
Statistical Significance ◽  
Experimental Studies ◽  
Time Of Flight ◽  
Metabolome Analysis ◽  
Flight Mass Spectrometry

Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD.

Quantitative Metabolome Analysis Using Capillary Electrophoresis Mass Spectrometry

2003 ◽  
Vol 2 (5) ◽  
pp. 488-494 ◽  
Author(s):  
Tomoyoshi Soga ◽  
Yoshiaki Ohashi ◽  
Yuki Ueno ◽  
Hisako Naraoka ◽  
Masaru Tomita ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Capillary Electrophoresis ◽  
Metabolome Analysis ◽  
Capillary Electrophoresis Mass Spectrometry

scholarly journals Serum Biomarker Identification by Mass Spectrometry in Acute Aortic Dissection

2017 ◽  
Vol 44 (6) ◽  
pp. 2147-2157 ◽  
Author(s):  
Yong Ren ◽  
Qizhu Tang ◽  
Wenwei Liu ◽  
Yongqian Tang ◽  
Rui Zhu ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Aortic Dissection ◽  
Peripheral Blood ◽  
Metabolic Pathways ◽  
Healthy Subjects ◽  
Ether Lipid ◽  
Intramural Hematoma ◽  
Differentially Expressed ◽  
Metabolome Analysis ◽  
Hypertensive Patients

Background/Aims: Aortic dissection (AD) is also known as intramural hematoma. This study aimed to screen peripheral blood biomarkers of small molecule metabolites for AD using high-performance liquid chromatography-mass spectrometry (HPLC-MS). Methods: Sera from 25 healthy subjects, 25 patients with well-established AD, and 25 patients with well-established hypertension were investigated by HPLC-MS to detect metabolites, screen differentially expressed metabolites, and analyze metabolic pathways. Results: Twenty-six and four metabolites were significantly up- and down-regulated in the hypertensive patients compared with the healthy subjects; 165 metabolites were significantly up-regulated and 109 significantly down-regulated in the AD patients compared with the hypertensive patients. Of these metabolites, 35 were up-regulated and 105 down-regulated only in AD patients. The metabolites that were differentially expressed in AD are mainly involved in tryptophan, histidine, glycerophospholipid, ether lipid, and choline metabolic pathways. As AD alters the peripheral blood metabolome, analysis of peripheral blood metabolites can be used in auxiliary diagnosis of AD. Conclusion: Eight metabolites are potential biomarkers for AD, 3 of which were differentially expressed and can be used for auxiliary diagnosis of AD and evaluation of treatment effectiveness.

Sign in / Sign up

Export Citation Format

Share Document